Roam Robotics Launches Partnership with the San Francisco VA Health Care System

To study the impact of its robotic wearable on the Veteran population

Roam Robotics, the company leading the expansion of human mobility with wearable robotics, announced today that the San Francisco VA Health Care System (SFVAHCS), along with the Northern California Institute for Research and Education (NCIRE), has begun enrolling patients to study the impact of Ascend, a first-of-its-kind smart brace, on the Veteran population.

Ascend, from Roam Robotics, is a smart knee orthosis designed to provide relief from knee pain and intuitively support everyday mobility. A previous clinical study of knee osteoarthritis participants demonstrated an average of 46 percent pain reduction, and 67 percent exhibited functional improvement when using the device.  Ascend is the first wearable robotic device to show usefulness in everyday life for people suffering from knee joint pain who want to regain independence and live more active lifestyles.  Ascend is also registered with the FDA as a Class I medical device.

“I am excited to evaluate Roam Robotics’ Ascend powered knee-brace in Veterans with knee osteoarthritis who experience considerable knee pain when performing day-to-day activities,” said Dr. Alfred Kuo, Chief of Orthopedic Surgery at the San Francisco VA Health Care System “Veterans suffer from musculoskeletal conditions such as knee arthritis at higher rates than the general population.  We don’t have great treatment options for many of these patients, especially ones who have moderate disease. The Ascend brace has the potential to substantially improve pain, stability, and function.”

Ascend provides a non-opioid and non-surgical solution for pain relief and increased stability, while performing common movements like walking, kneeling, standing, sitting, and going up or down steps. “Roam’s technology has been proven previously to provide benefits to a wide variety of patients suffering from knee pain, weak quadriceps or instability,” said Sujit Dike, Vice President at Roam Robotics. “We are very excited about this partnership with the   San Francisco VA. It can further validate the potential impact of Roam’s technology in addressing an enormous and growing challenge for the Veteran population”.

“Roam is focused on a massively underserved market.  More than 20 percent of the global population is limited by their body’s mobility, and as medical advancements help people live longer that number is only going to increase,” said Tim Swift, Roam’s CEO and Founder.  “Our approach to wearable robotics works seamlessly with the human body to help people lead healthier, happier and more active lives, unhindered by physical limitations.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”